Skip to content
CCCCC4 Therapeutics, Inc.

Earnings

When C4 Therapeutics, Inc. reports, what it reported each quarter, and how the stock took the results.

14 quarters. Sep 30, 2019 to Sep 30, 2026. USD.

Next results · Q4 2026Projected

Feb 25, before the open

Thu, Feb 25, 2027in 99 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Feb 22 – Mar 2

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
$11.02M
Revenue, change from a year earlier: Q3 2026 −24.6%, Q2 2026 +2.8%, Q1 2026 −15.0%, Q4 2025 +112.8%
Net income
-$20.49M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Quarter by quarter

Q3 2026$8.47M−24.6% vs Q3 2025

Latest results

  1. Q3 2026Nov 5, 2026, before the openThe release5.1%by the close of Nov 5
    Revenue
    $8.47M
    −24.6%
    Net income
    -$21.84M
    N/M
    EPS
    -$0.16
    N/M
    On November 5, 2026, C4 Therapeutics, Inc. (the “ Company ”) issued a press release announcing its financial results and business highlights for the quarter ended September 30, 2026.
  2. Q2 2026Aug 11, 2026, before the openThe release+6.6%by the close of Aug 11
    Revenue
    $6.64M
    +2.8%
    Net income
    -$23.64M
    N/M
    EPS
    -$0.18
    N/M
  3. Q1 2026May 12, 2026, before the openThe release+0.2%by the close of May 12
    Revenue
    $6.15M
    −15.0%
    Net income
    -$25.13M
    N/M
    EPS
    -$0.20
    N/M
  4. Q4 2025Feb 26, 2026, before the openThe release+0.2%by the close of Feb 26
    Revenue
    $11.02M
    +112.8%
    Net income
    -$20.49M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Nov 5, 2026 · pre-marketNov 5, 202636 d10-Q$8.47M−24.6%-$0.165.1%
Q2 2026Jun 30, 2026Aug 11, 2026 · pre-marketAug 11, 202642 d10-Q$6.64M+2.8%-$0.18+6.6%
Q1 2026Mar 31, 2026May 12, 2026 · pre-marketMay 12, 202642 d10-Q$6.15M−15.0%-$0.20+0.2%
FY 2025
Q4 2025derivedDec 31, 2025Feb 26, 2026 · pre-marketFeb 26, 202657 d10-K$11.02M+112.8%—+0.2%
Q3 2025Sep 30, 2025Nov 6, 2025 · pre-marketNov 6, 202537 d10-Q$11.23M—-$0.44+0.4%
Q2 2025Jun 30, 2025Aug 7, 2025 · pre-marketAug 7, 202538 d10-Q$6.46M—-$0.37+31.1%
Q1 2025Mar 31, 2025May 7, 2025 · pre-marketMay 7, 202537 d10-Q$7.24M—-$0.37+6.8%
FY 2024
Q4 2024derivedDec 31, 2024Feb 27, 2025 · pre-marketFeb 27, 202558 d10-K$5.18M+58.8%—1.5%
Earlier years, FY 2019 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 5, 2026070575
10-QAug 11, 2026055494
10-QMay 12, 2026033865
10-KFeb 26, 2026012000
10-QNov 6, 2025049854
10-QAug 7, 2025038587
10-QMay 7, 2025022866
10-KFeb 27, 2025008433
10-QOct 31, 2024044411
10-QAug 1, 2024033882

Provenance

ProvenanceData status and checks

C4 Therapeutics, Inc. · CIK 1662579 · Engraved from SEC EDGAR